Status | Study |
Active, not recruiting |
Study Name: A Phase II Study to Evaluate the Efficacy and the Safety of Flumatinib in CML-AP or CML-BP Patients Condition: Chronic Myelogenous Leukemia Date: 2015-07-26 Interventions: Drug: Flumatinib mesylate tablet 600 mg qd Flumatinib mesylate tablet 600 mg qd in CML-AP or CML-BP pati |
Completed |
Study Name: Enteropathogenic Escherichia Coli (EPEC): Does it Have a Role in Colorectal Tumourigenesis? Condition: Enteropathogenic Escherichia Coli . Colorectal Carcinoma Date: 2015-02-16 Interventions: Other: colonoscopic biopsies |
Active, not recruiting |
Study Name: Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML Condition: Adult Acute Megakaryoblastic Leukemia (M7) Adult Acute Minimally Differentiated Myeloid Leuk Date: 2013-05-06 Interventions: Drug: metformin hydrochloride |
Recruiting |
Study Name: Nilotinib-Chemotherapy in CML Myeloid BP or Bcr-abl(+) AML Condition: Chronic Myeloid Leukemia in Myeloid Blast Crisis Untreated Adult Acute Myeloid Leukemia Date: 2012-09-11 Interventions: Drug: Nilotinib+AD induction • Post-remission consol |
Completed |
Study Name: Gene Expression in Samples From Patients With T-Cell Acute Lymphoblastic Leukemia Condition: Leukemia Lymphoma Date: 2012-01-26 Interventions: Genetic: gene expression analysis Other: l |
Recruiting |
Study Name: An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357) Condition: Leukemia Date: 2011-12-21 Interventions: Drug: Dasatinib Starting Dose: |
Active, not recruiting |
Study Name: Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer Condition: Adult Solid Neoplasm Hormone-Resistant Prostate Cancer Rec Date: 2011-11-23 Interventions: Drug: Akt Inhibitor MK2206 Giv |
Completed |
Study Name: Prevention for the Development of Liver Tumorigenesis by the Oral Supplementation of Branched-chain Amino Acids Condition: Liver Cancer Date: 2011-09-13 Interventions: Drug: LIVACT LIVACT contains 13.0 g of free amino acids |
Completed |
Study Name: Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial Condition: Chronic Myelogenous Leukemia Date: 2011-06-06 Interventions: Drug: nilotinib Other Name: AMN107 |
Completed |
Study Name: Biomarkers in Tissue Samples From Young Patients With Liver Cancer Condition: Childhood Hepatoblastoma Stage I Childhood Liver Cancer St Date: 2011-04-15 Interventions: Genetic: RNA analysis Genetic: gene expres |